Asset Details
Do you wish to reserve the book?
LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy
Do you wish to request the book?
LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy
2017
Overview
Alzheimer＇s disease （AD） is a progressive neurodegenerative disease leading to the irreversible loss of brain neurons and cognitive abilities, and the vicious interplay between oxidative stress （OS） and tauopathy is believed to be one of the major players in AD development. Here, we demonstrated the capability of the small molecule N-（1,3-benzodioxol-5-yl）-2-[5-chloro-2- methoxy（phenylsulfonyl）anilino]acetamide （LX2343） to ameliorate the cognitive dysfunction of AD model rats by inhibiting OS-induced neuronal apoptosis and tauopathy. Streptozotocin （STZ） was used to induce OS in neuronal cells in vitro and in AD model rats that were made by intracerebroventricular injection of STZ （3 mg/kg, bilaterally）, and Morris water maze test was used to evaluate the cognitive dysfunction in ICV-STZ rats. Treatment with LX2343 （5-20 pmol/L） significantly attenuated STZ-induced apoptosis in SH-SY5Y cells and mouse primary cortical neurons by alleviating OS and inhibiting the JNK/p38 and pro-apoptotic pathways. LX2343 was able to restore the integrity of mitochondrial function and morphology, increase ATP biosynthesis, and reduce ROS accumulation in the neuronal cells. In addition, LX2343 was found to be a non-ATP competitive GSK-3β inhibitor with ICso of 1.84＋0.07 pmol/L, and it potently inhibited tau hyperphosphorylation in the neuronal cells. In ICV-STZ rats, administration of LX2343 （7, 21 mg·kg^-1·d^-1, ip, for 5 weeks） efficiently improved their cognitive deficits. LX2343 ameliorates the cognitive dysfunction in the AD model rats by suppressing OS-induced neuronal apoptosis and tauopathy, thus highlighting the potential of LX2343 for the treatment of AD.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ AD模型
/ Alzheimer Disease - drug therapy
/ Animals
/ Biomedical and Life Sciences
/ Cognitive Dysfunction - drug therapy
/ Cortex
/ Male
/ Maze Learning - drug effects
/ Nootropic Agents - therapeutic use
/ Original
/ Oxidative Stress - drug effects
/ Rats
/ Rodents
/ Sulfonamides - therapeutic use
/ tau蛋白
/ Vaccine
/ 大鼠
/ 氧化应激
/ 神经细胞凋亡
/ 认知功能障碍
/ 认知障碍
/ 诱导
